THERAPEUTIC USES OF LAG3 THE (alpha)-SYNUCLEIN TRANSMISSION RECEPTOR
AssigneesThe Johns Hopkins University, University of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsTed M. Dawson, Valina L. Dawson, Han Seok Ko, Xiaobo Mao, Dario Angelo Alberto Vignali, Creg J. Workman
Life of this patent
Estimating the term…
Abstract
Described are methods of inhibiting neurodegeneration in a subject by administering to the subject an agent that prevents (alpha)-syn PFF from binding to its receptor. The agent may be a small molecule chemical compound, antibody, nucleic acid molecule, or polypeptide. Drug screening methods are also provided.
Claims23
A method of inhibiting neurodegeneration in a subject comprising administering to the subject an agent that prevents α-syn PFF from binding to its receptor.
A method of drug screening comprising the steps of:
- providing one or more agent(s);
- applying the one or more agents to LAG3, and
- identifying those agents that prevent α-syn PFF from binding to LAG3.
A method of drug screening comprising the steps of:
- providing one or more agent(s);
- applying the one or more agents to cells, and
- identifying those agents that prevent α-syn PFF from binding to LAG3 or that inhibit the phosphorylation of α-syn PFF at serine 129.
Dependencies are inferred from the claim text.